Off-Label Promotion: FDA Commissioner's Concerns Stem From Ethics Of Informed Consent
This article was originally published in The Pink Sheet Daily
Executive Summary
'My personal view is that companies controlling that information is not the ideal,' Robert Califf tells BIO. 'That doesn’t mean I’ll carry the day.'
You may also be interested in...
Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Operation Warp Speed’s Difficult Holiday Season
The US missed even its revised year-end target for COVID vaccines, but the news isn’t all bad; there’s steady progress on clinical research even as federal officials seem out of ideas for how to speed actual vaccinations.
Pfizer Vaccine Shortfalls: Warp Speed’s Perna Takes Responsibility, Cites Lot Release Confusion
States had received less than they expected, and Operation Warp Speed and Pfizer had taken swipes at each other, but that all seems smoothed over now – even though it’s still not exactly clear how much of Pfizer’s COVID vaccine will be available to the US by the end of year.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: